For Appetite Control, Drugs vs. Diet for Weight Control

lucagon-like peptide-1 (GLP-1) agonists are among the newer tools in the obesity armamentarium. They reduce energy intake, leading to significant weight loss, with the added benefit of reducing blood glucose concentrations.
At the same time, they present issues regarding sustainability, cost, and adverse effects. In a study of 4,255 GLP-1 medication users conducted by the Blue Cross Blue Shield affiliate Prime Therapeutics, 68% of users discontinued treatment within the first year.
 
View News Details